Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.

Long-term Activity Ratios (Summary)
Net Fixed Asset Turnover
Total Asset Turnover
Equity Turnover

Gilead Sciences Inc., long-term (investment) activity ratios (quarterly data)

	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
Net fixed asset turnover	4.70	4.90	4.91	5.03	5.16	5.31	5.41	5.76	6.23	7.11	7.79	8.72	9.31	9.80	10.45	11.48	12.29	13.34	14.13	—	—	—
Total asset turnover	0.39	0.37	0.36	0.37	0.35	0.35	0.34	0.34	0.35	0.37	0.37	0.42	0.47	0.50	0.53	0.55	0.64	0.68	0.62	—	—	—
Equity turnover	1.21	1.01	0.98	1.07	0.97	1.00	1.01	0.96	1.05	1.18	1.26	1.09	1.24	1.40	1.59	1.85	2.06	2.42	1.73	—	—	—

Long-term activity ratio	Description	The company
Net fixed asset turnover	An activity ratio calculated as total revenue divided by net fixed assets.	Gilead Sciences Inc.’s net fixed asset turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Total asset turnover	An activity ratio calculated as total revenue divided by total assets.	Gilead Sciences Inc.’s total asset turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.
Equity turnover	An activity ratio calculated as total revenue divided by shareholders’ equity.	Gilead Sciences Inc.’s equity turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Gilead Sciences Inc., net fixed asset turnover calculation (quarterly data)

	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
Selected Financial Data (US$ in millions)
Product sales	5,067	5,467	5,796	5,516	5,607	5,200	5,681	5,455	5,540	5,001	5,837	6,402	7,046	6,377	7,216	7,405	7,651	7,681	8,409	8,211	8,126	7,405
Property, plant and equipment, net	4,653	4,564	4,502	4,377	4,249	4,116	4,006	3,791	3,659	3,415	3,295	3,100	3,012	2,922	2,865	2,714	2,599	2,431	2,276	2,143	1,899	1,765
Long-term Activity Ratio
Net fixed asset turnover¹	4.70	4.90	4.91	5.03	5.16	5.31	5.41	5.76	6.23	7.11	7.79	8.72	9.31	9.80	10.45	11.48	12.29	13.34	14.13	—	—	—
Benchmarks
Net Fixed Asset Turnover, Competitors²
Abbott Laboratories	3.77	4.06	3.97	4.01	3.95	4.03	4.04	4.08	3.98	3.71	3.60	3.48	3.24	3.07	3.66	3.61	3.53	3.49	3.56	—	—	—
AbbVie Inc.	7.38	11.50	11.23	11.36	11.33	11.42	11.36	10.91	11.10	10.47	10.07	10.11	10.05	10.04	9.85	9.57	9.46	9.16	8.91	—	—	—
Amgen Inc.	4.78	4.68	4.51	4.55	4.58	4.59	4.54	4.51	4.48	4.44	4.37	4.45	4.41	4.41	4.41	4.39	4.41	4.36	4.27	—	—	—
Biogen Inc.	4.35	4.39	4.43	4.54	4.57	4.58	3.74	3.74	3.78	3.78	3.86	3.95	4.14	4.42	4.58	4.78	4.88	4.84	4.92	—	—	—
Bristol-Myers Squibb Co.	6.03	5.07	4.18	5.00	4.92	4.67	4.49	4.33	4.25	4.16	4.15	4.10	4.09	3.98	3.90	3.86	3.83	3.80	3.75	—	—	—
Eli Lilly & Co.	2.88	2.92	2.83	2.90	2.96	3.08	2.75	2.75	2.72	2.61	2.59	2.61	2.56	2.56	2.57	2.53	2.55	2.51	2.48	—	—	—
Illumina Inc.	3.77	4.00	3.99	3.95	3.99	3.99	3.10	3.06	3.00	2.99	2.96	3.01	2.97	3.30	3.36	3.74	4.52	5.85	6.48	—	—	—
Johnson & Johnson	4.57	4.75	4.65	4.79	4.72	4.80	4.79	4.89	4.85	4.62	4.50	4.47	4.41	4.46	4.52	4.45	4.44	4.40	4.41	—	—	—
Merck & Co. Inc.	2.99	3.15	3.11	3.22	3.20	3.19	3.18	3.27	3.27	3.24	3.23	3.27	3.31	3.32	3.31	3.32	3.29	3.19	3.16	—	—	—
Pfizer Inc.	3.49	3.61	3.71	3.87	3.97	4.00	4.01	3.80	3.83	3.77	3.79	3.89	3.91	3.97	3.97	4.01	3.84	3.75	3.55	—	—	—
Regeneron Pharmaceuticals Inc.	2.64	2.71	2.72	2.75	2.70	2.65	2.61	2.52	2.52	2.53	2.49	2.43	2.32	2.19	2.33	2.53	2.62	2.66	2.57	—	—	—
Vertex Pharmaceuticals Inc.	7.42	6.55	5.59	4.93	4.72	4.40	3.75	3.50	3.21	3.02	3.15	3.02	2.88	2.85	2.44	2.42	2.26	1.87	1.48	—	—	—
Zoetis Inc.	3.15	3.21	3.23	3.39	3.48	3.51	3.51	3.68	3.80	3.75	3.70	3.69	3.70	3.62	3.54	3.53	3.62	3.66	3.65	—	—	—

¹ Q2 2020 Calculation
Net fixed asset turnover = (Product sales_{Q2 2020} + Product sales_{Q1 2020} + Product sales_{Q4 2019} + Product sales_{Q3 2019}) ÷ Property, plant and equipment, net
= (5,067 + 5,467 + 5,796 + 5,516) ÷ 4,653 = 4.70

² Click competitor name to see calculations.

Long-term activity ratio	Description	The company
Net fixed asset turnover	An activity ratio calculated as total revenue divided by net fixed assets.	Gilead Sciences Inc.’s net fixed asset turnover ratio deteriorated from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Gilead Sciences Inc., total asset turnover calculation (quarterly data)

	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
Selected Financial Data (US$ in millions)
Product sales	5,067	5,467	5,796	5,516	5,607	5,200	5,681	5,455	5,540	5,001	5,837	6,402	7,046	6,377	7,216	7,405	7,651	7,681	8,409	8,211	8,126	7,405
Total assets	55,934	59,741	61,627	59,146	63,210	62,837	63,675	64,305	65,355	65,381	70,283	64,662	60,263	57,701	56,977	56,609	49,980	47,765	51,839	50,637	39,167	38,321
Long-term Activity Ratio
Total asset turnover¹	0.39	0.37	0.36	0.37	0.35	0.35	0.34	0.34	0.35	0.37	0.37	0.42	0.47	0.50	0.53	0.55	0.64	0.68	0.62	—	—	—
Benchmarks
Total Asset Turnover, Competitors²
Abbott Laboratories	0.46	0.48	0.47	0.46	0.45	0.45	0.46	0.42	0.43	0.40	0.36	0.35	0.33	0.31	0.40	0.52	0.52	0.51	0.49	—	—	—
AbbVie Inc.	0.24	0.37	0.37	0.55	0.57	0.58	0.55	0.49	0.50	0.43	0.40	0.40	0.40	0.40	0.39	0.38	0.37	0.44	0.43	—	—	—
Amgen Inc.	0.36	0.37	0.37	0.37	0.38	0.35	0.34	0.33	0.33	0.31	0.27	0.27	0.28	0.28	0.28	0.28	0.29	0.28	0.29	—	—	—
Biogen Inc.	0.57	0.55	0.53	0.52	0.54	0.52	0.53	0.52	0.54	0.48	0.52	0.51	0.54	0.54	0.50	0.52	0.52	0.53	0.55	—	—	—
Bristol-Myers Squibb Co.	0.27	0.24	0.20	0.42	0.43	0.67	0.64	0.65	0.66	0.64	0.62	0.61	0.61	0.61	0.58	0.55	0.54	0.53	0.52	—	—	—
Eli Lilly & Co.	0.55	0.56	0.57	0.60	0.60	0.63	0.56	0.54	0.56	0.53	0.51	0.52	0.54	0.57	0.55	0.55	0.56	0.58	0.56	—	—	—
Illumina Inc.	0.46	0.49	0.48	0.49	0.49	0.46	0.48	0.48	0.53	0.53	0.52	0.51	0.51	0.53	0.56	0.56	0.58	0.59	0.60	—	—	—
Johnson & Johnson	0.51	0.53	0.52	0.53	0.52	0.54	0.53	0.52	0.52	0.50	0.49	0.48	0.47	0.50	0.51	0.51	0.51	0.52	0.53	—	—	—
Merck & Co. Inc.	0.52	0.57	0.55	0.55	0.53	0.52	0.51	0.49	0.49	0.47	0.46	0.43	0.43	0.41	0.42	0.41	0.41	0.40	0.39	—	—	—
Pfizer Inc.	0.28	0.30	0.31	0.31	0.34	0.35	0.34	0.32	0.32	0.32	0.31	0.30	0.31	0.31	0.31	0.30	0.31	0.31	0.29	—	—	—
Regeneron Pharmaceuticals Inc.	0.55	0.51	0.53	0.55	0.55	0.54	0.57	0.59	0.62	0.65	0.67	0.63	0.65	0.64	0.70	0.69	0.75	0.75	0.73	—	—	—
Vertex Pharmaceuticals Inc.	0.53	0.54	0.50	0.48	0.49	0.50	0.49	0.61	0.60	0.61	0.70	0.72	0.65	0.69	0.59	0.64	0.61	0.52	0.41	—	—	—
Zoetis Inc.	0.49	0.55	0.54	0.55	0.55	0.54	0.54	0.55	0.65	0.63	0.62	0.55	0.64	0.65	0.64	0.63	0.65	0.65	0.60	—	—	—

¹ Q2 2020 Calculation
Total asset turnover = (Product sales_{Q2 2020} + Product sales_{Q1 2020} + Product sales_{Q4 2019} + Product sales_{Q3 2019}) ÷ Total assets
= (5,067 + 5,467 + 5,796 + 5,516) ÷ 55,934 = 0.39

² Click competitor name to see calculations.

Long-term activity ratio	Description	The company
Total asset turnover	An activity ratio calculated as total revenue divided by total assets.	Gilead Sciences Inc.’s total asset turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Gilead Sciences Inc., equity turnover calculation (quarterly data)

	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019	Dec 31, 2018	Sep 30, 2018	Jun 30, 2018	Mar 31, 2018	Dec 31, 2017	Sep 30, 2017	Jun 30, 2017	Mar 31, 2017	Dec 31, 2016	Sep 30, 2016	Jun 30, 2016	Mar 31, 2016	Dec 31, 2015	Sep 30, 2015	Jun 30, 2015	Mar 31, 2015
Selected Financial Data (US$ in millions)
Product sales	5,067	5,467	5,796	5,516	5,607	5,200	5,681	5,455	5,540	5,001	5,837	6,402	7,046	6,377	7,216	7,405	7,651	7,681	8,409	8,211	8,126	7,405
Total Gilead stockholders’ equity	18,027	22,067	22,525	20,604	22,616	21,951	21,387	22,861	21,672	20,591	20,442	24,845	22,677	20,441	18,887	16,868	15,536	13,398	18,534	17,414	16,287	17,180
Long-term Activity Ratio
Equity turnover¹	1.21	1.01	0.98	1.07	0.97	1.00	1.01	0.96	1.05	1.18	1.26	1.09	1.24	1.40	1.59	1.85	2.06	2.42	1.73	—	—	—
Benchmarks
Equity Turnover, Competitors²
Abbott Laboratories	1.03	1.06	1.03	0.99	0.98	0.99	1.00	0.99	0.97	0.91	0.89	0.78	0.75	0.71	1.02	1.00	0.99	0.98	0.96	—	—	—
AbbVie Inc.	2.46	—	—	—	—	—	—	—	—	8.33	5.54	4.08	4.44	5.25	5.53	3.90	4.39	5.12	5.79	—	—	—
Amgen Inc.	2.17	2.41	2.30	2.04	2.07	2.07	1.80	1.54	1.48	1.40	0.86	0.68	0.69	0.71	0.73	0.70	0.72	0.74	0.75	—	—	—
Biogen Inc.	1.28	1.15	1.08	1.02	1.09	1.00	1.03	0.96	1.05	0.90	0.97	0.92	1.01	1.00	0.94	0.94	0.99	1.06	1.15	—	—	—
Bristol-Myers Squibb Co.	0.71	0.62	0.51	1.37	1.49	1.53	1.61	1.62	1.75	1.64	1.77	1.39	1.38	1.38	1.20	1.18	1.18	1.18	1.16	—	—	—
Eli Lilly & Co.	5.61	7.50	8.56	6.69	8.35	9.66	2.50	1.86	2.07	1.61	1.97	1.51	1.56	1.54	1.52	1.34	1.41	1.34	1.37	—	—	—
Illumina Inc.	0.73	0.77	0.77	0.78	0.79	0.85	0.89	0.93	0.95	0.98	1.00	0.91	0.92	0.95	1.09	1.06	1.13	1.13	1.20	—	—	—
Johnson & Johnson	1.28	1.35	1.38	1.40	1.34	1.38	1.37	1.26	1.28	1.24	1.27	1.01	1.01	1.03	1.02	0.98	0.98	0.97	0.98	—	—	—
Merck & Co. Inc.	1.71	1.83	1.81	1.71	1.61	1.56	1.58	1.29	1.27	1.21	1.17	1.04	1.01	1.00	0.99	0.91	0.91	0.90	0.88	—	—	—
Pfizer Inc.	0.76	0.78	0.82	0.81	0.90	0.92	0.85	0.75	0.76	0.72	0.74	0.86	0.90	0.90	0.89	0.84	0.83	0.81	0.75	—	—	—
Regeneron Pharmaceuticals Inc.	0.88	0.66	0.71	0.73	0.74	0.73	0.77	0.81	0.86	0.92	0.96	0.91	0.95	1.02	1.09	1.05	1.14	1.18	1.12	—	—	—
Vertex Pharmaceuticals Inc.	0.72	0.75	0.68	0.69	0.68	0.69	0.69	0.97	0.98	1.01	1.23	1.28	1.28	1.35	1.47	1.63	1.59	1.35	1.10	—	—	—
Zoetis Inc.	2.13	2.30	2.31	2.30	2.51	2.55	2.67	2.70	2.84	2.78	3.00	2.58	2.93	3.08	3.29	3.08	3.58	4.14	4.46	—	—	—

¹ Q2 2020 Calculation
Equity turnover = (Product sales_{Q2 2020} + Product sales_{Q1 2020} + Product sales_{Q4 2019} + Product sales_{Q3 2019}) ÷ Total Gilead stockholders’ equity
= (5,067 + 5,467 + 5,796 + 5,516) ÷ 18,027 = 1.21

² Click competitor name to see calculations.

Long-term activity ratio	Description	The company
Equity turnover	An activity ratio calculated as total revenue divided by shareholders’ equity.	Gilead Sciences Inc.’s equity turnover ratio improved from Q4 2019 to Q1 2020 and from Q1 2020 to Q2 2020.

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data

Long-term Activity Ratios (Summary)

Net Fixed Asset Turnover

Total Asset Turnover

Equity Turnover

Gilead Sciences Inc. (NASDAQ:GILD)

Analysis of Long-term (Investment) Activity RatiosQuarterly Data

Long-term Activity Ratios (Summary)

Net Fixed Asset Turnover

Total Asset Turnover

Equity Turnover

Analysis of Long-term (Investment) Activity Ratios
Quarterly Data